Short answer
STAAR SURGICAL CO (STAA) filed its fiscal 2026 10-K annual report with the SEC on Mar 3, 2026.
- Top risk flagged: Termination of Alcon Merger Agreement January 2026; $17.1 million Merger transaction costs in fiscal 2025
STAAR SURGICAL CO FY2026 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: development and sales of Implantable Collamer Lenses (ICLs) for treatment of myopia and refractive errors
- New product emphasis: full launch of EVO+ premium larger optic lens in China and planned introduction of additional lens sizes for surgical flexibility
- Strategic shift: heightened focus on growth, investment, and innovation amid market headwinds, including leadership realignment and cost reductions in 2025
- Quantitative metric: net sales decline 23.7% in 2025 to $239.4M driven by 32% drop in APAC region, especially China; R&D spend $40.1M (16.7% of sales)
- Noteworthy fact: terminated proposed merger with Alcon in early 2026 after incurring $17.1M merger-related costs in 2025
Management Discussion & Analysis
- No revenue, profitability, segment, cash flow, or forward-looking data disclosed in the MD&A section provided
Risk Factors
- Termination of Alcon Merger Agreement January 2026; $17.1 million Merger transaction costs in fiscal 2025
- China macroeconomic downturn causing net sales drop from $313.9M in 2024 to $239.4M in 2025, with China distributor sales down from $162.3M to $77.8M
- Dual manufacturing sites in U.S. and Switzerland increasing costs, pressuring gross margins due to lower site utilization
- Elevated China distributor inventory post-2024 led to reduced 2025 purchases, creating channel inventory risk and sales volatility
- Key-person and governance risks from Cooperation Agreement with largest stockholder Broadwood involving leadership changes and $7.0 million reimbursement
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.